GSK3B and cancer: miR-1246 dependent downregulation of GSK-3β [40] in lung cancer cells; THBS2 [55, 56] in cervical cancer cells; CADM1 [57] and RORα [58] in hepatocellular carcinoma cells; DENND2D [42] in oral squamous cell carcinoma cells; FRK [41] in glioma cells; as well as FOX2A [37] in melanoma cells; has been shown to enhance the invasive capacity of cancer cells.